Investigation of potential breath biomarkers for the early diagnosis of breast cancer using gas chromatography–mass spectrometry
Introduction
Breast cancer (BC) remains the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in women [1]. Early diagnosis is very important for reducing the BC mortality rate. However, the early diagnosis of BC is limited because the disease usually develops asymptomatically, while the conventional diagnostic techniques still have some shortcomings [2]. Therefore, there is still an urgent clinical need to improve or alternate these methods. The combination of molecular screening methods with these conventional methods may help improve this situation [2]. Cancer cells release molecular biomarkers into the blood during their growth, which can provide prognostic symbols that could be useful in early cancer diagnosis through breath, blood, and urine analyses [3], [4], [5], [6]. Breath analysis is noninvasive, easy to perform, painless, and present no risks, thus it may allow the development of convenient and safe method that could complement blood and urine tests [7].
Human exhaled breath (EB) mainly comprises N2, CO2, O2, water vapor, inert gases, volatile organic compounds (VOCs) and nonvolatile substances [8], [9]. These VOCs are either produced endogenously via metabolism or absorbed exogenously from the environment. Some additional compounds are produced and/or their concentrations are changed in pathological states of the body [10]. Endogenous biomarkers are commonly used for diagnostic purposes.
There is a considerable experimental evidence that the volatile components in EB can be used to detect neoplasms [9], [11], [12]. The theoretical basis for diagnosing BC based on breath analysis is speculative as follows. BC is accompanied by increased oxidative stress (OS), which can lead to DNA, proteins and lipid damages. The induction of cytochrome P450 enzymes leads to lipid peroxidation of polyunsaturated fatty acids in the cell membranes and resulting in overexpression of volatile alkanes and alkane-derivatives in the breath, and eventually affecting the abundance of VOCs in the EB [13], [14], [15]. Besides, free radical-induced oxidation of amino acids and proteins has also been demonstrated to result in the generation of some hydrocarbons along with malonaldehyde [16], [17], [18].
Only a limited number of studies have been performed to investigate the feasibility of BC diagnosis based on breath analysis. The published data show that the patterns of VOCs in the EB can distinguish patients with and without BC [19], [20], [21]. Unfortunately, the reported potential breath biomarkers for BC differ among studies [22]. Therefore, there is still a need to continue searching breath biomarkers for BC.
The growing interest in the discovery of breath biomarkers of the OS associated with lung cancer, especially straight aldehydes [23], [24], [25], led us to consider whether straight aldehydes are potential effective breath biomarkers for BC. Besides, there have been articles reported that formaldehyde [26] and heptanal [20] may be potential BC breath biomarkers. Aldehydes are secondary breakdown products of lipids oxidation [27], [28]. In particular, C5–C10 monofunctional aldehydes (including hexanal, heptanal, octanal, and nonanal) have been identified to be derived from lipid peroxidation [28]. The well-understood biochemical pathways of these aldehydes simplify the evaluation of their diagnostic values. In addition, volatile aldehydes have low solubility in the blood, so they are excreted into the breath within minutes after their formation in tissues [9], [29]. Furthermore, hexanal, heptanal, octanal and nonanal were relatively stable than low molecular weight aldehydes and they all could be detected by our method. Moreover, we found that their levels seem to be different between HC and BC in our preliminary experiment results. Therefore, among a variety of straight aldehydes, we choose to study hexanal, heptanal, octanal and nonanal.
Elevated levels of aldehydes imply enhanced OS and they have been proposed as a measure for cancer status diagnosis [30], [31], [32]. Moreover, the pattern of aldehydes appeared to be unique to each form of cancer [31]. Hexanal, heptanal, some alkanes, alkane derivatives, and benzene derivatives [33], pentanal, hexanal, octanal, and nonanal [24] were reported to be potential breath biomarkers for lung cancer. Furthermore, formaldehyde [26] and heptanal [20] was also reported as potential breath biomarkers for BC. Therefore, we and other researchers have proposed that exhaled aldehydes are potential diagnostic biomarkers for various human cancers, including BC [20], [22], [24], [26], [33], [34].
Although Fuchs et al. [24] found out that exhaled aldehydes could be used as lung cancer biomarkers, they only focus on lung cancer. Peng et al. [35] achieved the discrimination between ‘healthy’ and ‘cancerous’ breath in a variety of human cancers (including lung, breast, colorectal, and prostate cancers) by a nanosensor array. To the best of our knowledge, no previous studies have evaluated in detail the clinical value of identifying BC using specific volatile straight aldehydes in EB by simple direct gas chromatography–mass spectrometry (GC–MS) analysis without any preconcentration.
Therefore, we designed a systematic study to investigate and identify novel potential breath aldehyde biomarkers for the early diagnosis of BC. Based on literature survey [22], [23], [24], [31], [32] and preliminary experiment results, we choose hexanal, heptanal, octanal and nonanal (which were relatively stable than low molecular weight aldehydes, and were often reported as potential tumor biomarkers, as well as their biochemical pathways were well understood) as our target compounds.
Section snippets
Chemicals and calibration standards
Hexanal (98%) was obtained from Sigma-Aldrich. Heptanal (97%), octanal (99%), and nonanal (96%) were from Aladdin Chemistry. Absolute ethanol (analytical grade) was purchased from Chengdu Tianhua Chemical Industry. The standard aldehyde solutions were prepared in absolute ethanol.
The standard stock aldehyde solution mixtures (hexanal: 3.98 × 10− 2 mol/l, 2.39 × 10− 2 mol/l, 1.59 × 10− 2 mol/l, 7.96 × 10− 3 mol/l, 1.99 × 10− 3 mol/l, 9.95 × 10− 4 mol/l, 7.96 × 10− 5 mol/l; heptanal: 3.61 × 10− 2 mol/l, 2.17 × 10− 2 mol/l, 1.44 × 10− 2
Determination of the 4 BC biomarkers in human breath samples using GC–MS
Separating the target metabolites from other metabolites is a crucial problem in target metabolite analysis. Furthermore, it has been reported that the VOCs in the EB vary among subjects, and on the whole, most breath samples contain more than 200 different VOCs [40]. Therefore, the separation column is of critical importance, so our first aim was to identify a GC–MS separation column that could provide good separation of breath samples. To select the column, we first tested the widely used
Discussion
The concentrations of many exhaled VOCs are relatively low, so most cannot be detected by direct GC–MS analysis. However, direct GC–MS analysis without tedious sample pretreatment procedures may be simpler, more reliable, and preferable to the analysis of exhaled VOCs at relatively higher concentrations. In this study, we found that about 30 peaks could still be found in the EB by direct GC–MS analysis. To the best of our knowledge, this is the first combined application of a DB-624 column and
Abbreviations
- EB
exhaled breath
- BC
breast cancer
- BBT
breast benign tumor
- HC
healthy controls
- VOCs
volatile organic compounds
- OS
oxidative stress
- ER
Estrogen receptor
- PR
progesterone receptor
Acknowledgments
The authors are grateful to the financial support from the National Science Foundation of China (No. 21305095), National Recruitment Program of Global Experts (NRPGE), the Hundred Talents Program of Sichuan Province (HTPSP), and the Startup Funding of Sichuan University for setting up the Research Center of Analytical Instrumentation.
References (45)
- et al.
Diagnostic potential of breath analysis-focus on volatile organic compounds
Clin Chim Acta
(2004) - et al.
A hydrogen peroxide sensor for exhaled breath measurement
Sens Actuators B
(2005) - et al.
Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure
Toxicol Appl Pharmacol
(2008) - et al.
Generation of volatile hydrocarbons from amino acids and proteins by an iron/ascorbate YGSH system
Biochem Pharmacol
(1990) - et al.
Phenylhydrazine-induced lipid peroxidation of red blood cells in vitro and in vivo: monitoring by the production of volatile hydrocarbons
Biochem Pharmacol
(1984) - et al.
Diagnosis of breast cancer based on breath analysis: an emerging method
Crit Rev Oncol Hematol
(2013) - et al.
Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME–GC/MS
J Chromatogr B
(2010) - et al.
Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chromatography–mass spectrometry
J Chromatogr B Analyt Technol Biomed Life Sci
(2004) - et al.
Quantitative analysis by gas chromatography of volatile carbonyl compounds in expired air from mice and human
J Chromatogr B
(1997) Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer
J Thorac Oncol
(2008)
Cytotoxic aldehydes as possible markers for childhood cancer
Free Radic Biol Med
Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study
Lancet
Breath biomarkers in diagnosis of pulmonary diseases
Clin Chim Acta
Determination of aldehydes in human breath by on-fibre derivatization, solid-phase microextraction and GC–MS
J Chromatogr B Analyt Technol Biomed Life Sci
Breath acetone monitoring by portable Si:WO3 gas sensors
Anal Chim Acta
Variation in volatile organic compounds in the breath of normal humans
J Chromatogr B
Applications of breath gas analysis in medicine
Int J Mass Spectrom
From highly sophisticated analytical techniques to life-saving diagnostics: technical developments in breath analysis
TrAC Trends Anal Chem
Cancer statistics, 2013
CA Cancer J Clin
Biomarkers in molecular medicine: cancer detection and diagnosis
Biotechniques
Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models
J Eval Clin Pract
Potential of urinary biomarkers in early bladder cancer diagnosis
Expert Rev Anticancer Ther
Cited by (97)
A journey from omics to clinicomics in solid cancers: Success stories and challenges
2024, Advances in Protein Chemistry and Structural BiologyHarnessing insect olfactory neural circuits for detecting and discriminating human cancers
2023, Biosensors and Bioelectronics